IDH-targeted PET/MRI for diagnosing and grading gliomas
Official title: Construction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of Gliomas
Run by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · NCT07405372 · Data updated 2026-11-12
This project tests whether an IDH-targeted PET/MRI scan can find IDH mutations in adults with suspected or known glioma to help with diagnosis, grading, and treatment planning.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Chongqing, Chongqing Municipality) |
| Status | Recruiting |
| Started | December 1, 2025 |
| Main results expected | December 1, 2027 |
| Study ends | December 1, 2027 |
| Registry record updated | February 24, 2026 |
| Trial ID | NCT07405372 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with suspected, newly diagnosed, or previously treated glioma who can provide informed consent and tolerate MRI/PET imaging are ideal candidates.
✕Probably not a fit
Patients who cannot undergo MRI (for example due to incompatible implants or severe claustrophobia), pregnant or breastfeeding individuals, or those with recent excessive radiation exposure are not eligible and would not benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study uses a PET/MRI protocol with an IDH-targeted tracer to image adult patients with suspected, newly diagnosed, or previously treated gliomas. Investigators will collect clinical and biological data, record PET metrics such as lesion location, size, SUVmax, and calculate target-to-background ratios, and compare imaging findings with pathological analysis including H&E and immunohistochemistry for IDH status. The goal is to build a noninvasive in vivo tracing platform and evaluation system to support precision diagnosis and prognostic evaluation. Imaging and pathology data will be correlated to determine how well the PET/MRI signature identifies IDH-mutant versus IDH-wildtype tumors.
Why it matters
Potential benefit: If successful, this approach could allow noninvasive determination of IDH mutation status to guide more precise diagnosis, targeted therapy choices, and prognosis for glioma patients.
How similar studies have gone: Early preclinical work and some small clinical reports of IDH-targeted imaging have shown promise, but broad clinical validation remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient ≥ 18 years of age at the time of consent; * Patients with suspected, newly diagnosed, or previously treated gliomas; * Provided written informed consent authorisation before participating in the study. Exclusion Criteria: * Pregnancy or lactation; * MRI contraindications, not limited to cardiac implantable electronic devices and claustrophobia; * Participants with radiation exposure exceeding 50 mSv in the past year.
Where it's running
-
Department of Nuclear Medicine, Daping Hospital of Army Medical University
Chongqing, Chongqing Municipality, China Recruiting
Study contacts
- Principal investigator: Xiao Chen — Daping Hospital, Army Medical University
- Study coordinator: Xiao Chen
- Email: xiaochen229@foxmail.com
- Phone: 15922970174
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Proton vs. Photon Radiation for Certain Grade 2–3 Gliomas
This study tests whether proton therapy can better preserve thinking and memory than photon therapy for adults with IDH-mutated grade 2–3 gliomas who need radiation.
-
Connectome-guided network planning for brain tumor surgery in eloquent areas
This study tests whether using patient-specific brain network maps from diffusion MRI can help surgeons plan and guide brain tumor removal in eloquent areas.
-
AI-powered analysis of brain MRI to help glioma care
Doctors will use AI to study existing MRI scans and patient data from adults with glioma to see if it can help with non-invasive diagnosis and treatment planning.
-
Safusidenib in IDH1-mutant glioma after vorasidenib progression
This trial tests safusidenib in people with IDH1-mutant glioma who progressed on vorasidenib and did not need immediate chemo or radiation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.